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Abstract
© The Author(s). Recent findings indicate that the ubiquitin-proteasome system is involved in
the pathogenesis of cancer as well as autoimmune and several neurodegenerative diseases,
and is thus a target for novel therapeutics. One disease that is related to aberrant protein
degradation  is  multiple  sclerosis,  an  autoimmune  disorder  involving  the  processing  and
presentation of myelin autoantigens that leads to the destruction of axons. Here, we show that
brainderived  proteasomes from SJL  mice  with  experimental  autoimmune encephalomyelitis
(EAE) in an ubiquitinindependent manner generate significantly increased amounts of myelin
basic protein peptides that induces cytotoxic lymphocytes to target mature oligodendrocytes ex
vivo. Ten times enhanced release of immunogenic peptides by cerebral proteasomes from EAE-
SJL  mice  is  caused  by  a  dramatic  shift  in  the  balance  between  constitutive  and  β1ihigh
immunoproteasomes in  the  CNS of  SJL  mice  with  EAE.  We found that  during  EAE,  β1i  is
increased in resident CNS cells, whereas β5i is imported by infiltrating lymphocytes through the
blood-brain  barrier.  Peptidyl  epoxyketone  specifically  inhibits  brain-derived  β1ihigh
immunoproteasomes in vitro (kobs/[I] = 240 M-1s-1), and at a dose of 0.5 mg/kg, it ameliorates
ongoing EAE in vivo. Therefore, our findings provide novel insights into myelin metabolism in
pathophysiologic conditions and reveal that the β1i subunit of the immunoproteasome is a
potential target to treat autoimmune neurologic diseases.
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